Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | WNT1 | P04628 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.33 |
| ▸ | CLK3 | P49761 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.33 |
| ▸ | DNM1L | O00429 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873035 | 0.82 | PHGDH (0.36) | DYRK1AWNT1GSK3BROCK2ROCK1 | |
| SCHEMBL5872959 | 0.81 | ALDH1A1 (0.42) | DYRK1ACLK2CLK3MAPTMAPK1 | |
| SCHEMBL5872927 | 0.75 | ALDH1A1 (0.41) | DYRK1ACLK2CLK3MAPTMAPK1 | |
| SCHEMBL5873016 | 0.71 | KDM4E (0.44) | MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL5873066 | 0.71 | MEN1 (0.42) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL5873133 | 0.70 | TACR3 (0.42) | DYRK1ACLK2CLK3MAPTMAPK1 | |
| SCHEMBL5873193 | 0.70 | DYRK1A (0.41) | DYRK1AWNT1CLK2CLK3PIM1 | |
| SCHEMBL5873067 | 0.70 | MKNK1 (0.43) | PIM1 | |
| SCHEMBL5769525 | 0.70 | PIM1 (0.41) | DYRK1AWNT1CLK2CLK3PIM1 | |
| SCHEMBL5767627 | 0.69 | MAP2K4 (0.43) | DYRK1AWNT1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | DYRK1A 1836/4885WNT1 3712/4885GSK3B 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.